相关实验视频
Updated: Jul 14, 2025

08:03
In Vitro Model of Coronary Angiogenesis
Published on: March 10, 2020
7.8K
血管内皮生长因子-A的抑制降低了牛皮的血管生成:一个试点研究
Andrea Luengas-Martinez1, Dina Ismail1, Ralf Paus1,2,3,4
1Centre for Dermatology Research and Manchester Academic Health Science Centre The University of Manchester Manchester UK.
Skin health and disease
|October 6, 2023
概括
血管内皮生长因子-A (VEGF-A) 的抑制减少了牛皮皮肤样本中的血管形成. 这表明抗VEGF-A疗法可能是牛皮的潜在治疗方法.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 血管新生研究研究
背景情况:
- 血管内皮生长因子-A (VEGF-A) 驱动血管生成,有助于牛皮的发病.
- 抗血管性疗法已在瘤学和眼科中建立,但尚未用于牛皮管理.
研究的目的:
- 研究VEGF-A阻断对皮肤血管,表皮和牛皮的免疫细胞的ex vivo影响.
主要方法:
- 用抗VEGF-A抗体 (bevacizumab) 或同型控制培养牛皮斑块和非损伤性皮肤的器官培养.
- 对CD31/LYVE-1,Ki-67和巨细胞合酶进行定量免疫组织形态测量.
- 测量VEGF-A水平在血,PBMCs和培养超水生物中的测量.
主要成果:
- 抑制VEGF-A有效地阻断了 ex vivo 的自由VEGF-A.
- 在牛皮斑中减少血管面积和内皮细胞数量.
- 治疗疗效与皮肤上浮体和患者血中的VEGF-A水平相关.
结论:
- 第一个体外研究表明了VEGF-A抑制在牛皮的潜力.
- 数据支持进一步的临床试验,用于抗VEGF-A治疗牛皮,特别是严重病例或高VEGF-A水平的患者.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Mechanism of Angiogenesis
5.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
180
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
180

